Nivolumab

The FDA granted accelerated approval to nivolumab plus ipilimumab for treatment of patients with hepatocellular carcinoma who previously received sorafenib.

Neoadjuvant nivolumab with or without ipilimumab appeared effective and safe for patients with resectable oral cavity cancer, according to results of a randomized phase 2 study presented at Multidisciplinary Head and Neck Cancers Symposium.

The FDA granted priority review to the combination of nivolumab plus ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK mutations, according to a press release from the agents’ manufacturer.

Cervical Cancer Awareness Month is observed every January.

ORLANDO — Polyfunctional strength index on pretherapy bone marrow CD4-positive T cells differed substantially between responders and nonresponders to azacitidine plus nivolumab for relapsed or refractory acute myeloid leukemia, according to results of a nonrandomized phase 2 study presented at ASH Annual Meeting and Exposition.

Soft tissue sarcoma is a rare type of cancer that affects the body’s soft tissues, such as muscles, fat and ligaments. There are more than 50 types of soft tissue sarcoma, including synovial sarcoma, which accounts for 5% to 10% of all soft tissue tumors diagnosed each year.

A discussion with the author of a study that found direct-to-consumer genetic tests had an “alarming” rate of clinical false-negative results for two limited variant screening tests — including the test for BRCA1 and BRAC2 — was last week’s top story in hematology/oncology.

NATIONAL HARBOR, Md. — The combination of sitravatinib and nivolumab induced encouraging clinical activity among patients with advanced urothelial carcinoma who experienced progression after immune checkpoint inhibitor therapy, according to results of a phase 2 study presented at Society for Immunotherapy of Cancer Annual Meeting.

The FDA granted the combination of nivolumab and ipilimumab priority review and breakthrough therapy designation for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib, according to a company-issued press release.

Lung Cancer Awareness Month — observed every November — is intended to educate the public about the potential causes and risk factors of the disease.